Long-term results of cornea collagen cross-linking with riboflavin for keratoconus

Indian J Ophthalmol. 2013 Aug;61(8):433-4. doi: 10.4103/0301-4738.116072.

Abstract

Corneal collagen cross-linking with riboflavin and UVA light (CXL) is the only method designed to arrest the progression of keratoconus. Visual improvement generally starts 3 months after treatment. Reduction is coma seen on aberrometry in early postoperative phase is also responsible for the improvement in visual acuity. In the light of currently available data we can thus say that CXL is a safe procedure that is successful in arresting keratoconus.

Publication types

  • Review

MeSH terms

  • Collagen / metabolism*
  • Corneal Stroma / metabolism*
  • Corneal Topography
  • Cross-Linking Reagents / therapeutic use*
  • Humans
  • Keratoconus / drug therapy*
  • Keratoconus / metabolism
  • Photochemotherapy* / methods
  • Photosensitizing Agents / therapeutic use*
  • Riboflavin / therapeutic use*
  • Treatment Outcome
  • Ultraviolet Rays
  • Visual Acuity / physiology

Substances

  • Cross-Linking Reagents
  • Photosensitizing Agents
  • Collagen
  • Riboflavin